Converting Guanfacine ER 1 mg Daily to IR Formulation
Do not substitute guanfacine extended-release (ER) for immediate-release (IR) on a milligram-for-milligram basis, as the pharmacokinetic profiles differ significantly between formulations 1, 2.
Key Pharmacokinetic Differences
The ER and IR formulations have fundamentally different absorption and elimination profiles that prevent direct dose conversion:
- Guanfacine ER 1 mg cannot be simply replaced with guanfacine IR 1 mg because the extended-release formulation provides sustained drug levels over 24 hours, while IR requires multiple daily doses 1, 2
- Research demonstrates that 3 mg/day of IR guanfacine produces similar plasma levels to 4 mg/day of ER guanfacine after 24 hours from last dose 3
- Using this ratio, 1 mg ER would theoretically correspond to approximately 0.75 mg IR, though this extrapolation lacks clinical validation
Critical Safety Considerations
You must taper guanfacine rather than abruptly discontinue it to avoid rebound hypertension 4, 5. This applies when switching formulations:
- Rebound hypertension can occur 2-4 days after abrupt discontinuation 5
- The delayed rebound (compared to clonidine) reflects guanfacine's longer half-life 5
- Most patients return to pretreatment blood pressure levels slowly within 2-4 days without ill effects when properly tapered 5
Practical Switching Strategy
Given the lack of established conversion protocols and safety concerns:
- Overlap the formulations during transition rather than direct substitution
- Start IR at a low dose (0.5-1 mg at bedtime) while continuing ER temporarily
- Gradually taper the ER formulation over several days while monitoring response
- Monitor cardiovascular parameters closely: heart rate and blood pressure should be checked regularly during the transition 4
- Assess for withdrawal symptoms: irritability, headache, or blood pressure elevation
Dosing Considerations for IR Formulation
Once transitioned to IR guanfacine 5:
- Initial dose: 1 mg daily at bedtime to minimize somnolence
- If inadequate response after 3-4 weeks, may increase to 2 mg daily
- Most therapeutic effect is seen at 1 mg 5
- Doses above 3 mg/day significantly increase adverse reactions 5
Common Pitfalls to Avoid
- Never assume 1:1 dose equivalence between ER and IR formulations—this is explicitly contraindicated 1, 2
- Do not abruptly stop the ER formulation when initiating IR due to rebound hypertension risk 4, 5
- Avoid switching in patients with cardiovascular risk factors without additional evaluation, as both formulations can affect heart rate and blood pressure 4
Monitoring During Transition
Watch for:
- Cardiovascular effects: decreased heart rate and blood pressure (expected pharmacologic effects) 4
- Common adverse effects: somnolence, dry mouth, dizziness, fatigue, constipation 5
- Withdrawal symptoms: if ER is tapered too quickly
- Loss of ADHD symptom control: IR may require dose optimization
The safest approach is a gradual cross-taper with close monitoring rather than direct substitution, given the lack of established conversion guidelines and the cardiovascular risks associated with abrupt discontinuation.